Literature DB >> 2299262

Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis.

A B Thompson1, T Bohling, F Payvandi, S I Rennard.   

Abstract

Lactoferrin and lysozyme are proteins found in high concentrations on mucosal surfaces, and they have activities potentially important for the modulation of inflammation. To investigate whether these proteins might contribute to the modulation of the intraluminal airway inflammation associated with chronic bronchitis, lactoferrin and lysozyme were measured in bronchoalveolar lavage (BAL) fluid from 22 subjects with chronic bronchitis and, for comparison, with 10 symptom-free smokers and 16 normal subjects. As a further control, transferrin, a protein structurally homologous to lactoferrin but not known to arise in airway epithelial cells, was also measured. BAL was performed by sequentially instilling and retrieving five 20 ml aliquots of normal saline solution into each of three sites. Analyzing the first aliquots separately from the later four provided fluid that was enriched for airway contents. The concentration of lactoferrin (11.83 +/- 2.86 micrograms/ml vs 0.68 +/- 0.18 micrograms/ml, p less than 0.00001), and lysozyme (6.75 +/- 1.51 micrograms/ml vs 0.52 +/- 0.09 microgram/ml, p less than 0.00001), but not transferrin (3.22 +/- 0.38 microgram/ml vs 2.68 +/- 0.24 micrograms/ml, p = 0.55) was higher in the bronchial sample lavage fluid, suggesting an airway origin for lactoferrin and lysozyme. In subjects with chronic bronchitis, bronchial sample lactoferrin (23.1 +/- 0.5 micrograms/ml) and lysozyme (12.6 +/- 3.5 micrograms/ml) were elevated compared with the normal subjects' lactoferrin (1.9 +/- 0.5 micrograms/ml, p less than 0.0001) and lysozyme (0.77 +/- 0.22 microgram/ml, p less than 0.0001) and the symptom-free smokers' lactoferrin (4.1 +/- 0.8 micrograms/ml, p = 0.005) and lysozyme (4.9 +/- 1.3 micrograms/ml, p = 0.02). Transferrin concentrations did not demonstrate the same relationships. Finally, when the content of bronchial sample lactoferrin and lysozyme were compared with the content of bronchial sample neutrophils, poor correlations were found, which may imply an airway epithelial origin for the two proteins. Thus lactoferrin and lysozyme appear to arise in the lower respiratory tract within the airways and their levels are elevated in association with chronic bronchitis. This suggests that lactoferrin and lysozyme may contribute to the modulation of airway inflammation in chronic bronchitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299262

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  43 in total

Review 1.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Alcohol use disorders affect antimicrobial proteins and anti-pneumococcal activity in epithelial lining fluid obtained via bronchoalveolar lavage.

Authors:  Ellen L Burnham; Jeanette Gaydos; Edward Hess; Robert House; Jacinta Cooper
Journal:  Alcohol Alcohol       Date:  2010-08-20       Impact factor: 2.826

3.  Bronchoalveolar lavage cell pattern from healthy human lung.

Authors:  M Heron; J C Grutters; K M ten Dam-Molenkamp; D Hijdra; A van Heugten-Roeling; A M E Claessen; H J T Ruven; J M M van den Bosch; H van Velzen-Blad
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

4.  Lactoferrin and secretory IgA in the bronchoalveolar lavage fluid from patients with a stable asthma.

Authors:  E A van de Graaf; T A Out; A Kobesen; H M Jansen
Journal:  Lung       Date:  1991       Impact factor: 2.584

5.  Killing of gram-negative bacteria by lactoferrin and lysozyme.

Authors:  R T Ellison; T J Giehl
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

Review 6.  Iron metabolism in the lower respiratory tract.

Authors:  F Mateos; J H Brock; J L Pérez-Arellano
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

Review 7.  Innate immunity in the respiratory epithelium.

Authors:  Dane Parker; Alice Prince
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-17       Impact factor: 6.914

8.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Mucin inhibits Pseudomonas aeruginosa biofilm formation by significantly enhancing twitching motility.

Authors:  Cecily L Haley; Cassandra Kruczek; Uzma Qaisar; Jane A Colmer-Hamood; Abdul N Hamood
Journal:  Can J Microbiol       Date:  2014-01-24       Impact factor: 2.419

10.  Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung.

Authors:  R Bals; X Wang; Z Wu; T Freeman; V Bafna; M Zasloff; J M Wilson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.